An advanced treatment for skin cancer that combines immunotherapy with mRNA vaccine technology has shown promising outcomes in a recent advanced trial, as announced by pharmaceutical companies Merck and Moderna on Wednesday. The new therapy, known as intismeran, demonstrated superior performance compared to immunotherapy alone in reducing melanoma recurrence and preventing cancer spread to other body parts in patients who had previously undergone melanoma surgery.
The companies reported that the results of the treatment were both statistically significant and clinically meaningful. However, medical professionals responded cautiously to the news, highlighting that the Phase 3 trial, which is the final stage before regulatory approval, is still ongoing, and the disclosed results are preliminary.
Dr. Marcus Butler, a medical oncologist at Toronto’s Princess Margaret Cancer Centre, expressed excitement about the development, citing positive outcomes from an earlier Phase 2 study. He emphasized that while the potential benefits of the treatment appear promising, it is still early to draw definitive conclusions.
Once the trial data are finalized and if the positive results are confirmed, it may still take over eight months before the treatment becomes accessible to Canadians, noted Dr. Ramy Saleh, an oncology associate professor at McGill University in Montreal. Saleh highlighted the challenges associated with scaling up a novel treatment globally and underscored the need for collaboration among government, healthcare authorities, and industry to address logistical and operational hurdles.
The treatment, which combines Merck’s pembrolizumab immunotherapy drug (Keytruda) with a customized mRNA vaccine from Moderna, targets neoantigens in cancer cells to train the immune system to identify and eliminate abnormal proteins. This dual approach involves activating the immune system with immunotherapy while providing instructions to combat cancer cells through mRNA vaccines.
Despite the potential benefits of the treatment, concerns remain about differentiating between general immune stimulation from mRNA vaccines and specific responses against melanoma neoantigens. Additionally, the trial focused solely on early-stage melanoma patients with completely removed tumors, emphasizing the need for further research to evaluate the treatment’s effectiveness in later-stage cases.
The study enrolled 1,137 high-risk patients with Stage IIB-IV melanoma who had undergone surgical removal of tumors, including Canadian participants. Volunteers were randomized to receive either Keytruda plus the personalized vaccine or Keytruda alone. The companies reported no new safety concerns arising from the trial.